Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea’s oncology drug candidate lisavanbulin, which has been developed as a potential therapy for glioblastoma, the most common type of primary brain cancer.
June 20, 2024
· 6 min read
